{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:11Z","timestamp":1790707211636,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":2852,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1111\/ajt.12969","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T12:13:35Z","timestamp":1418818415000},"page":"129-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Sirolimus Use and Cancer Incidence Among US Kidney Transplant Recipients"],"prefix":"10.1016","volume":"15","author":[{"given":"E.L.","family":"Yanik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.L.","family":"Kasiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Israni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Segev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.12969_bib1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplat recipients","volume":"306","author":"Engels","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1111\/ajt.12969_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: A meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/ajt.12969_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0305-7372(81)80006-0","article-title":"New antitumor substances of natural origin","volume":"8","author":"Douros","year":"1981","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/ajt.12969_bib4","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.7164\/antibiotics.37.1231","article-title":"Activity of rapamycin (AY-22,989) against transplanted tumors","volume":"37","author":"Eng","year":"1984","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1111\/ajt.12969_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/ajt.12969_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: A target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/ajt.12969_bib7","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J"},{"key":"10.1111\/ajt.12969_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mc.10140","article-title":"Involvement of the Akt\/mTOR pathway on EGF-induced cell transformation","volume":"38","author":"Nomura","year":"2003","journal-title":"Mol Carcinog"},{"key":"10.1111\/ajt.12969_bib9","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res"},{"key":"10.1111\/ajt.12969_bib10","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12969_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12969_bib12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajt.12969_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12969_bib14","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.7314\/APJCP.2012.13.9.4335","article-title":"Sirolimus and, non-melanoma skin cancer prevention after kidney transplantation: A meta-analysis","volume":"13","author":"Gu","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1111\/ajt.12969_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/TP.0b013e3182247ae2","article-title":"Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial","volume":"92","author":"Alberu","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12969_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.12969_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12969_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.trre.2013.01.002","article-title":"Scientific Registry of Transplant Recipients: Collecting, analyzing, and reporting data on transplantation in the United States","volume":"27","author":"Leppke","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1111\/ajt.12969_bib19","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1600-6143.2012.04130.x","article-title":"Report of a consensus conference on transplant program quality and surveillance","volume":"12","author":"Kasiske","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12969_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-010-0141-x","article-title":"Targeting mTOR in cancer: Renal cell is just a beginning","volume":"5","author":"Azim","year":"2010","journal-title":"Target Oncol"},{"key":"10.1111\/ajt.12969_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12032-009-9201-4","article-title":"The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma","volume":"27","author":"Zhou","year":"2010","journal-title":"Med Oncol"},{"key":"10.1111\/ajt.12969_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.urology.2012.11.030","article-title":"Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma","volume":"81","author":"Darwish","year":"2013","journal-title":"Urology"},{"key":"10.1111\/ajt.12969_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000334340","article-title":"Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma","volume":"79","author":"Kim","year":"2012","journal-title":"Pathobiology"},{"key":"10.1111\/ajt.12969_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: Effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1111\/ajt.12969_bib25","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajt.12969_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajt.12969_bib27","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.12969_bib28","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.12969_bib29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ajt.12969_bib30","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1111\/j.1600-6143.2008.02430.x","article-title":"The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer","volume":"8","author":"Chamie","year":"2008","journal-title":"Am J Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.12969","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522000909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522000909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:08:02Z","timestamp":1761628082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522000909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1600613522000909"],"URL":"https:\/\/doi.org\/10.1111\/ajt.12969","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus Use and Cancer Incidence Among US Kidney Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.12969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}